DGAP-News

Evotec launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb

DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec launches 'beLAB2122', translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb 13.04.2021 / 07:30 The issuer is solely responsible for the content of this announcement.

---

• beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY
• EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ
• BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122

Hamburg, Germany, 13 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Mediated and supported by BioRN, the Life Science Cluster Rhein Neckar, beLAB2122 for the first time brings together the European Molecular Biology Laboratory ("EMBL"), the German Cancer Research Center ("DKFZ"), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen in one collaboration with industry partners. Evotec's BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaborations provide an integrated fund and award framework to validate exciting academic projects in collaborations with pharma and funders which may lead to the formation of jointly owned new companies. Since 2016, Evotec has established several BRIDGE collaborations with a variety of academic, pharma, and venture capital partners across Europe and North America.